Cellarity has dosed the first subject in a Phase I study of oral medication, CLY-124, to treat sickle cell disease (SCD).

Extreme pain, known as a pain crisis, is one of the hallmark symptoms of SCD. With frequent hospitalizations, chronic pain ...

Sickle cell disease is one of the most common inherited blood disorders worldwide, with a particularly heavy burden in sub-Saharan Africa. Every year, hundreds of thousands of infants are born with ...

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Sickle Cell Disease pipeline constitutes 55+ key companies continuously working towards developing 60+ Sickle Cell ...

At Miami-Dade’s public hospital system Jackson Health, new advancements in genetic research recently helped doctors modify a ...

With gene therapy in the works, clinical trials for sickle cell disease still lack Black American participants.

The World Health Organization has released its first-ever global guideline on the management of sickle cell disease during ...

BEAM-101, a treatment for sickle cell disease, showed sustained efficacy and safety over one year in the BEACON Phase 1/2 ...

Dr. Omar H. Llaguna, specialist in surgical oncology, programs a HistoSonics medical device for targeting a medium that ...